Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Plans to advance diverse pipeline of programs in oncology and metabolic diseases
Anticipates key proof-of-concept readouts for TERN-701 (CML) and TERN-601 (obesity) in 2H24
Related news for (TERN)
- Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
- Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight Report, 2025 – Featuring Analysis of Inventiva Pharma, Cirius Therapeutics, Terns Pharmaceuticals, HighTide Biopharma, Eli Lilly and Company, and More
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
- Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer